Navigation Links
Histogen Wins Appellate Court Hearing in SkinMedica Patent Case

San Diego, CA (PRWEB) August 26, 2013

Histogen, Inc., a regenerative medicine company developing solutions based on the products of cells grown under simulated embryonic conditions, today announced that the United States Court of Appeals for the Federal Circuit has affirmed a lower court decision that the Company does not infringe patents in the lawsuit that SkinMedica, Inc. filed against Histogen in 2009.

SkinMedica had previously sued the Company for infringement of United States Patent Nos. 6,372,494 (titled “Methods of making conditioned cell culture medium compositions”) and 7,118,746 (titled “Conditioned cell culture medium compositions and methods of use”). In 2011, the United States District Court for the Southern District of California granted the Company’s Motion for Summary Judgment, confirming a finding of noninfringement. SkinMedica appealed the Summary Judgment Order, and on August 23, 2013 was rebuffed again by the Federal Circuit.

“We are excited to have confirmation from the Federal Circuit Court of Appeals that Histogen’s technology is unique, and outside of SkinMedica’s patent rights,” said Dr. Gail K. Naughton, Histogen CEO and Chairman of the Board. “We look forward to continuing the rapid revenue growth we’re seeing in our skincare business through our current partners, bringing on new partners in the near future, and expanding the skin care line to other aesthetic applications.”

Histogen’s proprietary human multipotent cell conditioned media is the key ingredient in the ReGenica line of skincare products within the United States, and will be incorporated into additional cosmetic products in various countries through promising partnerships.

The Federal Circuit Court of Appeals affirmed the grant of Motion for Summary Judgment in case 2012-1560 following a hearing on May 9, 2013. A copy of the appellate court opinion is available upon request.

About Histogen
Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen’s technology focuses on stimulating a patient’s own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Histogen Creates PUR Biologics, a Joint Venture Developing Next-Generation, Biologic Solutions in Orthopedic Applications
2. Genetic Testing Explodes after Supreme Court Patent Decision
3. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
4. Honey Bee Beekeeping Class at North Island College’s Courtenay Campus
5. Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment
6. Bed Bugs are On The Rise in Courts and Apartment Complexes; My Cleaning Products Offers Complimentary Samples of Its Bed Bug Spray To Bed Bug Victims
7. Non-Toxic Bed Bug Spray Offers Complimentary Sample to Court After a Man Infected It With Bed Bugs, My Cleaning Products Explains How Others Could Get a Sample
8. Indoor Air Quality Professionals Provide New Expert Witness Services To Help Mold Victims Get Mold Claims Approved and Win in Court, AGCEnvironmental Explains How
9. Case Zeltiq - CLINIPRO: The Court Upholds Clinipro - LipoCryo Claim
10. Three Blockbuster Patent Cases at the Supreme Court This Term
11. Appeal Courts Direction on Claim Construction Is Strategically Important for Butamaxs Case Against Gevo Scheduled for April 2013
Post Your Comments:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: ... for financial services, but it also plays a fundamental part ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):